Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy
Objective To evaluate and to compare quality of life of patients with non- metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme. Method: Descriptive prospective study during 24 months (October 2015- October 2017) for patients with non-metastasic colorectal cancer in chemoth...
Saved in:
| Main Authors: | Julia Sánchez-Gundín, Ana María Fernández-Carballido, Ana Isabel Torres-Suárez, Dolores Barreda-Hernández |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11156.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01) -
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
by: FENG Huizhi, LIU Jingmei, BU Xiaoqian
Published: (2024-11-01) -
Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer
by: Julia Sánchez-Gundín, et al.
Published: (2019-09-01) -
FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study
by: Yan-Cen Lu, et al.
Published: (2024-11-01) -
Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer
by: Qian Fang, et al.
Published: (2025-03-01)